Meiji Seika Pharma Announces Positive Results in Phase II Study of ME3183, a Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Moderate-to-Severe Plaque Psoriasis in the United States and Canada
9.8.2023 09:00:00 EEST | Business Wire | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi) today announced that ME3183, a novel highly-potent selective phosphodiesterase-4 (PDE4) inhibitor, met the primary endpoint based on “PASI-75”, defined as the proportion of subjects achieving 75% improvement in Psoriasis Area Severity Index (PASI), in phase II clinical trial in patients with moderate-to-severe plaque psoriasis conducted in the United States and Canada.
The phase II clinical trial (NCT05268016)* was conducted to evaluate the efficacy, safety and tolerability of ME3183 after administered once or twice daily for 16 weeks in patients with moderate-to-severe plaque psoriasis. One-hundred and thirty-two patients were enrolled in the United States and Canada. The primary endpoint was defined as the proportion of subjects achieving 75% improvement (“PASI-75”) in Psoriasis Area Severity Index (PASI) Score at Week 16 from baseline. As a result, significantly greater proportion of PASI-75 achievement were observed in ME3183 treatment groups compared to the placebo group, which met the primary endpoint. In addition, early PASI improvement after administration was observed in ME3183 groups. ME3183 was shown to be safe and well tolerated. Details of the study will be presented at an upcoming medical meeting.
ME3183 is an orally-available and selective PDE4 inhibitor discovered by Meiji Seika Pharma. In non-clinical studies, it showed greater anti-inflammatory effect and approximately 30-fold greater inhibitory effect on TNF-α production than the existing orally-available PDE4 inhibitor for psoriasis. At the same time, the distribution of ME3183 in the brain was sufficiently low.
Meiji strives to provide efficacious and safe treatment for unmet medical needs, such as psoriasis and other autoimmune diseases.
*: Meiji Pharma USA Inc. (Teaneck, NJ, President: Yasushi Miyazawa), a wholly owned subsidiary of Meiji, is in charge of the Phase II clinical trial.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230808681726/en/
Contact information
Meiji Pharma USA Inc.
Yasushi Miyazawa
President
Telephone: 201-777-7133
E-mail: mpu.contact@meiji-us.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Specright Launches Automated PPWR Declaration of Conformity Reporting22.7.2026 07:00:00 EEST | Press release
Specright™, the leader in AI-powered Specification Data Management™ (SDM) and modern Product Lifecycle Management (PLM), today announced a new Declaration of Conformity (DoC) reporting capability that automates a core requirement of the EU's Packaging and Packaging Waste Regulation (PPWR). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721689027/en/ Specright's new capability automates PPWR Declaration of Conformity reporting ahead of the EU's August 2026 deadline. Companies placing packaged goods on the EU market must produce a signed DoC starting August 12, 2026, covering PPWR Articles 5 through 12 — substance restrictions, recyclability, recycled content, minimization, reusability, and labeling. For most brands, that documentation is scattered across suppliers and spreadsheets, turning routine filings into monthslong searches. "This launch builds on our EMEA investments this past year — from the PPWR-ready packaging in
MediaCo Appoints Brian Fisher as President21.7.2026 23:15:00 EEST | Press release
MediaCo Holding Inc. (Nasdaq: MDIA) today announced executive leadership appointments that align the Company's leadership structure to support its long-term growth strategy. Effective immediately, Brian Fisher has been appointed President of MediaCo. Albert Rodriguez will continue to serve as Chief Executive Officer, focusing on the Company's long-term strategy, growth initiatives and shareholder value, while Fisher assumes responsibility for leading the Company's day-to-day operations and execution. The Company also announced that Roberto Castro has been appointed Interim Chief Financial Officer and Interim Treasurer, overseeing the Finance organization while a search is conducted for a permanent Chief Financial Officer. "MediaCo has built tremendous momentum, and these leadership appointments position us well for our next phase of growth," said Albert Rodriguez, Chief Executive Officer of MediaCo. "Brian is the right leader to serve as President, and Roberto's financial expertise wil
Footprint Expands Into PE-Free Cups, Bringing a Proven, Recyclable and Home-Compostable Alternative to Plastic-Lined Paper Cups Into Production21.7.2026 19:00:00 EEST | Press release
Footprint, a materials science and technology company focused on eliminating single-use plastics, today announced it has acquired a recyclable, home-compostable, polyethylene (PE)-free hot and cold cup platform from Transcend Packaging, along with next-generation paper lid and straw solutions. Transcend Packaging is a European company focused on innovation in sustainable packaging solutions. Together, the cup, lid, and straw expand Footprint’s portfolio with a proven solution for the global cup market. Footprint will begin scaling its new PE-free solution through its Poland facility as the company expands across Europe, with North America to follow. As operations ramp in Poland, Footprint will work with Transcend through a manufacturing partnership to support customer continuity across Europe and meet growing demand for practical alternatives to plastic-lined cups. Transcend will manufacture product from its Wales facility for Footprint customers, while continuing to serve customers in
Spectro Cloud Launches PaletteAI Inference Launchpad to Reduce Enterprise Token Costs by up to 70%21.7.2026 17:00:00 EEST | Press release
Spectro Cloud, a leading provider of AI infrastructure management software, today launched PaletteAI Inference Launchpad, a turnkey, locally managed solution designed to help enterprises reduce token costs by as much as 70% and run AI inference closer to their data, applications and users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721597271/en/ The company also announced expanded PaletteAI support for AMD-powered AI infrastructure, including AMD GPUs, AMD GPU Operator, ROCm™ runtime, and the AMD enterprise AI reference stack — including AMD-optimized models from the AMD Inference Microservices (AIMs) catalog. Together, the announcements expand PaletteAI as one platform for production AI infrastructure across heterogeneous environments — giving enterprises, neoclouds and sovereign cloud providers a more flexible path to run governed AI infrastructure across NVIDIA and AMD silicon. AI infrastructure is entering the tok
RecVue Launches First AI Native Agentic Revenue Operating System21.7.2026 16:03:00 EEST | Press release
RecVue, the leader in billing and revenue management solutions, today announced the evolution of RecVue RevOS into the industry's first Agentic Revenue Operating System. In an architectural shift, the now-native agentic revenue management platform moves revenue operations beyond AI-assisted workflows to fully governed, autonomous execution with more than 50 purpose-built agents that work across contracts, invoices and payment data to predict risk, surface anomalies and escalate exceptions throughout the quote-to-cash lifecycle. Enterprise revenue operations have long suffered from a structural gap between billing systems that generate invoices and ERP systems that record transactions. Finance teams face tedious, manual reconciliation month after month, often resulting in delayed cash, billing errors that generate disputes, revenue leakage from ungoverned contract changes and close cycles that consume weeks. “Enterprise RevOps has always demanded both speed and precision, but traditiona
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom